Zobrazeno 1 - 10
of 1 168
pro vyhledávání: ''
Autor:
Besse, Lenka, Besse, Andrej, Stolze, Sara C., Sobh, Amin, Zaal, Esther A., Ham, Alwin J.Van Der, Ruiz, Mario, Phuyal, Santosh, Buchler, Lorina, Sathianathan, Marc, Florea, Bogdan I., Boren, Jan, Hlman, Marcus Sta, Huber, Julia, Bolomsky, Arnold, Ludwig, Heinz, Hannich, J. Thomas, Loguinov, Alex, Everts, Bart, Berkers, Celia R., Pilon, Marc, Farhan, Hesso, Vulpe, Christopher D., Overkleeft, Herman S., Driessen, Christoph, Veterinaire biochemie, Sub Biomol.Mass Spectrometry & Proteom., dB&C FR-RMSC RMSC, Biomolecular Mass Spectrometry and Proteomics
Publikováno v:
Cancer Research, 81(17), 4581. American Association for Cancer Research Inc.
Cancer Research, 81(17), 4581-4593
Cancer Res
Cancer Research, 81(17), 4581-4593. AMER ASSOC CANCER RESEARCH
Cancer Research, 81(17), 4581-4593
Cancer Res
Cancer Research, 81(17), 4581-4593. AMER ASSOC CANCER RESEARCH
The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)–refractory multiple myeloma, nelfinavir-based therapy resulted in 65% parti
Autor:
Sung Chul Lim, Youngnam Cho, Y. J. Kim, Seungmin Kang, Kyu Min Kim, Moon-Chang Baek, Keon Wook Kang, Miso Park, Ju Hyun Bae, Sung Baek Jeong, Jin Ki Kim, Dae Won Jun, Yong June Choi, Seung-Hyun Lee, Jiwon Kim, Wankyu Kim, HyungJae Lee, Sung Yun Cho
Publikováno v:
Cancer Research. 81:3539-3553
Extracellular vesicles (EV) in the tumor microenvironment have emerged as crucial mediators that promote proliferation, metastasis, and chemoresistance. However, the role of circulating small EVs (csEV) in cancer progression remains poorly understood
Autor:
Eunice Y. Lau, Man Tong, Katherine Po Sin Chung, Terence K. Lee, Stephanie Ma, Rainbow Wing Hei Leung, Etienne H. Mok, Irene Oi-Lin Ng, Martina Mang Leng Lei, Q Zhao, Vincent W. Keng, Carmen Oi Ning Leung, Hoi Wing Leung, Cong Ma
Publikováno v:
Cancer Research. 81:3229-3240
The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance, however, inhibitors that spec
Autor:
Pelin Gülizar Ersan, Hong Pei, Joel Linden, Sara Serra, Kim Phan, Qiping Zhao, Caglar Cekic, Renee Clift, H. Michael Shepard, Lei Huang, Michael J. LaBarre, Mertkaya Aras, Christopher D. Thanos, Lin Wang, Ozgur Sahin, Jessica Cowell, Xiaoming Li, Silvia Deaglio, Luz Marina Londoño, Ozge Saatci
Publikováno v:
Cancer Research. 81:3319-3332
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can target adenosine for cancer therapy has not been inv
Autor:
Hsin-Fang Tu, Ming-Shyue Lee, Geen-Dong Chang, Santiago Ramón-Maiques, Chia-Chi Ku, Der-Yen Lee, Chao-Chi Ho, Hsin-Ying Lin, Ching-Tai Lee, Francisco Del Caño-Ochoa, Chun-Jung Ko, Ya-Hui Chuang, I-Chun Chen, Shao-Wei Lan, Hsin-Hsien Lin, Cheng-Fan Lee
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
13 páginas, 7 figuras
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Autor:
Ki Hyun Yoo, Mi Hyeon Jang, Chang Hoon Cho, Alfredo Oliveros, Joseph A. Baur, Jason J. Tang, Mun Gyeong Bae, S. John Weroha, Jong Hoon Choi, Danielle Brogren, Xiaonan Hou, Mohammad Abdur Rashid, John R. Hawse, Ana Mia Corujo-Ramirez, Lindsey A Kirkeby
Publikováno v:
Cancer Res
Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic
Autor:
Zhe Zhi, Lei Chen, Yiming Hu, Yongping Shao, Yan Wang, Yibo Ren, Jiankang Liu, Shujun Han, Yuwei Yan, Yan Zheng
Publikováno v:
Cancer Research. 81:2918-2929
The long noncoding RNA (lncRNA) SAMMSON is required for human melanoma cell growth and survival. However, whether SAMMSON regulates the response of mutant BRAF melanoma cells to RAF inhibitors remains unknown. In this work, we showed that SAMMSON is
Autor:
Ladislav Merta, Natalia Torrealba, Jaroslav Truksa, Jan Stursa, Jiri Neuzil, Lukas Werner, Daniel Rösel, Veronika Tomkova, Kristyna Blazkova, Jan Brábek, Sandra Lettlova, Sukanya Balkrishna Jadhav, Miroslava Kari Adamcová, Cristian Sandoval-Acuña
Publikováno v:
Cancer Research. 81:2289-2303
Deferoxamine (DFO) represents a widely used iron chelator for the treatment of iron overload. Here we describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferentially target cancer cells. The agent showed mark
Autor:
Ke Cong, John J. Krais, Michelle Mosqueda, Sharon B. Cantor, Sumeet Nayak, Lihua Julie Zhu, Jianhong Ou, Min Peng, Matt Bere, Neil Johnson, Samuel M. Bond, Jennifer A. Calvo, Bin Deng, Nicholas J. Panzarino, Mihir B. Doshi
Publikováno v:
Cancer Res
Defects in DNA repair and the protection of stalled DNA replication forks are thought to underlie the chemosensitivity of tumors deficient in the hereditary breast cancer genes BRCA1 and BRCA2 (BRCA). Challenging this assumption are recent findings t
Autor:
David W. Cescon, Cunjie Zhang, Linda Z. Penn, Rosemary Yu, Emily Branchard, James W. Dennis, Richard R. Drake, Mohamad Elbaz, Joseph Longo, Jenna E. van Leeuwen
Publikováno v:
Cancer Research. 81:2625-2635
Aberrant N-glycan Golgi remodeling and metabolism are associated with epithelial–mesenchymal transition (EMT) and metastasis in patients with breast cancer. Despite this association, the N-glycosylation pathway has not been successfully targeted in